

Completion of Entitlement Offer

On 31 October 2023, Radiopharm Theranostics Limited (ASX:RAD) (**Radiopharm or Company**) announced the details of a non-renounceable entitlement offer (**Entitlement Offer**) to raise approximately \$10 million. Under the Entitlement Offer, eligible shareholders were able to subscribe for 1 new fully paid ordinary share in Radiopharm (**New Shares**) for every 2.35 fully paid ordinary shares in Radiopharm at the issue price of \$0.07 per New Share.

On 21 November 2023, Radiopharm extended the closing date of the Entitlement Offer to 5pm (AEDT) on 1 December 2023. Radiopharm received valid applications under the Entitlement Offer for 30,197,244 New Shares, raising an amount of approximately \$2.1 million.

Radiopharm's Managing Director, Mr Riccardo Canevari, said " I would like to thank shareholders who have participated in the rights issue. The funds raised will go towards supporting our prioritised programs."

Issue and allotment of the New Shares will occur today, and ASX trading of the New Shares is expected to commence on 11 December 2023.

A shortfall of approximately 114,190,261 New Shares (representing an amount of approximately \$8.0 million) remains. As the Entitlement Offer is not underwritten, the shortfall has not been issued and may be placed by the Company in accordance with the ASX listing rules.

The Directors thank all eligible shareholders who participated in the Entitlement Offer for their continuing support.

For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Automic Registry Services on 1300 288 664 (inside Australia) or +61 2 9698 5414 (outside Australia).

**Authorised on behalf of the Radiopharm Theranostics Limited's board of directors by
Executive Chairman Paul Hopper.**

Important information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to in this document have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

This document may not be distributed or released in the United States.

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Radiopharm does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.